Navigation Links
Drug improves survival of colorectal cancer patients, trial results show
Date:1/17/2012

ROCHESTER, Minn. An investigational drug called regorafenib slowed the progression of tumors and lengthened the lives of patients with metastatic colorectal cancer, an international phase III clinical trial found. The findings were presented today at the Gastrointestinal Cancers Symposium of the American Society of Clinical Oncology in San Francisco by Mayo Clinic oncologist Axel Grothey, M.D., principal investigator of the trial in the United States.

"For years, patients with metastatic colorectal cancer have faced a devastating impasse when standard chemotherapies have failed to halt the growth of tumors and physicians have run out of effective drugs to offer them," says Dr. Grothey. "This is the first novel agent in eight years to show improvement in overall survival of colon cancer patients who have run out of treatment options."

Researchers tested regorafenib in a phase III, randomized, placebo-controlled trial, conducted simultaneously in the United States, Europe, Japan, Australia and China. They looked at survival outcomes in 760 patients whose cancer had progressed despite standard chemotherapy regimens. Regorafenib is a multi-kinase inhibitor, which has the effect of slowing cell proliferation and blood vessel growth and tempering a variety of biological pathways that are activated in tumors.

Researchers found that patients with metastatic colon cancer who were treated with the drug showed a 29 percent increase in overall survival when compared to those treated with placebo. The median length of survival for patients treated with the drug increased from 5 months to 6.5 months, a statistically significant jump. Overall, regorafenib reduced patients' risk of dying from cancer during the trial by 23 percent.

The trial, whose largest group of study participants in the United States was at Mayo Clinic, finished more than a year ahead of schedule.

"Patients with metastatic colorectal cancer who have failed all approved standard therapies have a poor prognosis," says Dr. Grothey. "This is the first and only agent in this setting that has demonstrated statistically significant overall survival benefit."


'/>"/>

Contact: Joe Dangor
newsbureau@mayo.edu
507-284-5005
Mayo Clinic
Source:Eurekalert

Related medicine news :

1. New fibrosis classification improves accuracy of diagnosis in hepatitis C
2. Aquatic therapy soon after total knee arthroplasty improves outcomes
3. Long-term inhaled dry powder mannitol improves lung function in CF
4. Walking skills program improves physical function following hip replacement surgery
5. In-utero procedure for birth defect of the diaphragm significantly improves infant survival
6. Planting improves heart rate, stress levels of mentally challenged adults
7. Mayo Clinic research improves diagnosis and potential treatment of neuromyelitis optica
8. Virtual childbirth simulator improves safety of high-risk deliveries
9. Increasing dosage of clopidogrel for patients with genetic variation improves response to medication
10. Putting stroke patients in charge improves quality of life
11. Better understanding of neurologic defects improves post-cardiac-arrest discharge
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/5/2016)... ... December 05, 2016 , ... BSI and Brenntag Canada ... States and Canada for distribution of their natural fruits and beverage colorants ... is an exciting addition to our Life Sciences product portfolio,” said Steve Brauer, President ...
(Date:12/5/2016)... ... 2016 , ... Sideline Products is a Southern York County Pennsylvania-based premier designer ... and the horse. Smaller saddles can pinch and irritate the horse creating safety issues ... properly fitted western saddle so it does not impact the comfort or performance of ...
(Date:12/5/2016)... , ... December 05, 2016 , ... “Life Will Never ... a supportive family and friends. “Life Will Never Be The Same” is the creation ... course in writing children's books and holds a degree in Christian religion and philosophy ...
(Date:12/5/2016)... ... December 05, 2016 , ... Sabah Shah MD, MBA has joined the Retina Group of ... York was founded by James M. Maisel, MD and has been providing tertiary medical and ... followed a legacy of surpassing expectations amongst her peers. Growing up in a family ...
(Date:12/5/2016)... ... December 05, 2016 , ... ... ensure moisture measurements are consistently correct. However, regular performance testing is often ... TOLEDO offers a solution: SmartCal™ . This innovative test substance offers ...
Breaking Medicine News(10 mins):
(Date:12/5/2016)... LAKE OSWEGO, Ore. , Dec. 5, 2016 /PRNewswire/ ... in the BioInsight clinical study. The study evaluates the ... 2 insertion procedure in an office setting. ... ProMRI ® technology that is placed underneath a ... atrial fibrillation and syncope (fainting). Atrial fibrillation is a ...
(Date:12/5/2016)... Calif. , Dec. 5, 2016 Sanovas, ... technology accelerator, announced today the launch of its wholly owned ... Logo - http://photos.prnewswire.com/prnh/20161202/445250LOGO   Logo - http://photos.prnewswire.com/prnh/20161202/445251LOGO ... ... There ...
(Date:12/5/2016)... Dec. 5, 2016  Wellbridge Health and Gateway Health proudly ... solutions to Medicare and Medicaid plan members with specific high ... the unique needs of this group of consumers, Wellbridge combines ... philosophies to provide insight into members, daily behaviors and lifestyle. ... , , ...
Breaking Medicine Technology: